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Abstract
Objectives Increased (central) sympathetic activity is a
key feature of heart failure and associated with worse
prognosis. Animal studies suggest that statin therapy can
reduce central sympathetic outﬂow. This study assessed
statin effects on (central) sympathetic activity in human
chronic heart failure (CHF) patients.
Methods Sympathetic activity was measured in eight
patients with CHF patients during 8 weeks after discon-
tinuation and 4 weeks after restart of statin therapy by
microneurography for direct muscle sympathetic nerve
recording (MSNA) and measurement of arterial plasma
norepinephrine concentrations.
Results During discontinuation of statin therapy, MSNA
was signiﬁcantly increased (73 ± 4 vs. 56 ± 5 and 52 ± 6
bursts/100 beats, p = 0.01). Burst frequency was signiﬁ-
cantly higher after statin discontinuation (42 ± 3 burst/min
without statin vs. 32 ± 3 and 28 ± 3 burst/min during
statin therapy, p = 0.004). Mean normalized burst ampli-
tude and total normalized MSNA were signiﬁcantly higher
after statin discontinuation (mean normalized burst
amplitude 0.36 ± 0.04 without statin vs. 0.29 ± 0.04 and
0.22 ± 0.04 during statin, p\0.05; total normalized
MSNA 15.70 ± 2.78 without statin, vs. 9.28 ± 1.41 and
6.56 ± 1.83 during statin, p = 0.009). Arterial plasma
norepinephrine levels and blood pressure were unaffected.
Interpretation Statin therapy inhibits central sympathetic
outﬂow in CHF patients, as measured by MSNA.
Keywords Heart failure  Nervous system, sympathetic 
Statin  Catecholamines  HRV
Introduction
A number of cardiovascular conditions like chronic heart
failure (CHF) is characterized by an increased sympathetic
tone, reﬂecting the functional severity of CHF [4]. On the
long term, this sympathetic overactivity has been shown to
be detrimental, leading to an increased myocardial cell
death, arrhythmias, reduced survival and increased hospi-
talization and morbidity rates [1, 2, 16, 22]. Nowadays,
reduction of sympathoexcitation by speciﬁc treatment has
become a cornerstone in modern treatment of these con-
ditions. Beta-adrenergic receptor antagonists and angio-
tensin-converting enzyme (ACE) inhibitors have been
shown to increase survival and reduce morbidity [3, 24].
However, although these speciﬁc strategies shield target
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sympathetic nerve trafﬁc itself remains unaffected.
In an animal model of pacing-induced CHF, studies
have shown that 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors (statins) reduce the
enhanced sympathetic activity. However, the exact mech-
anism of this action of statins has not yet been clariﬁed [5].
The primary aim of the present study was to test the
hypothesis that statin therapy can inhibit sympathetic nerve
activity also in humans. In this proof-of-concept study, we
investigated patients with CHF because CHF is accompa-
nied by increased sympathetic activity. Since patients with
CHF are usually treated by statins, we hypothesized that
temporary discontinuation of their statin therapy would
increase sympathetic activity and restart of statin therapy
would reduce it again. If statins do reduce sympathetic
nerve activity in patients with CHF, this effect might
provide an additional explanation for the beneﬁcial effects
of statins in these patients [8].
Methods
Participants
Eight patients diagnosed with CHF according to the mod-
iﬁed Framingham Clinical Criteria, New York Heart
Association (NYHA) II-IV, were included in our study
[21]. Inclusion criteria were left ventricular ejection frac-
tion (LVEF) B40% as assessed by 2D echocardiography,
stable statin treatment for at least 3 months prior to the
study and sinus rhythm. Exclusion criteria were necessity
of short-term percutaneous coronary intervention, coronary
artery bypass grafting or heart transplantation, chronic
disease of the autonomic nervous system, diabetes mellitus,
an obligatory reason for not interrupting statin therapy (e.g.
recent myocardial or cerebral infarction), use of tricyclic
antidepressant drugs or a-adrenergic receptor antagonists
(or b-adrenergic receptor antagonists with a-adrenergic
receptor antagonizing properties). The investigation con-
forms with the principles outlined in the Declaration of
Helsinki. The institutional review committee approved the
study and informed consent was obtained from all patients
before participation in the study.
Study protocol
Sympathetic activity was assessed using different approa-
ches: direct measurement of muscle sympathetic nerve
activity (MSNA) by microneurography and measurement of
arterial plasma catecholamine concentrations. Effects on
blood pressure, heart rate and cholesterol levels were
recorded. Measurements were performed at 3 different time
points: during statin therapy (visit 1), 8 weeks after dis-
continuation (visit 2) and 4 weeks after restart of (original)
statin therapy (visit 3). Experiments were conducted at 8:00
a.m. after an overnight (10-h) fast with the patient in supine
position in a quiet temperature-controlled room (23–24C).
Subjects had to abstain from caffeine, tea, alcohol, choco-
latesandsmokingforatleast12 hpriortothetestprocedure.
All experiments were carried out after voiding to prevent
reﬂex sympathoexcitation. A catheter (Angiocath: 20-
gauge, 48 mm, Becton–Dickinson and Co., Sandy, Utah)
was inserted under local anesthesia (lidocaine 2%) into the
brachial artery to obtain arterial blood samples and to have
blood pressure measurements. After complete instrumenta-
tion,30 minofrestwereincludedtoreturntostablebaseline
conditions before data collection. Hereafter, arterial blood
samples were drawn and microneurography was performed.
Sympathetic nerve trafﬁc (microneurography)
The peroneal nerve was localized at the site of the ﬁbula
head using transdermal electrical impulses (40–60 mV,
0.2 ms, 1 Hz) by a small electrode. After localization, a
sterile Tungsten microelectrode was inserted manually
through the skin in the underlying peroneal nerve posterior
to the ﬁbular head. Electrode position within a muscle nerve
fascicle was identiﬁed by evoking muscle twitches by
electrical stimuli (1–5 mV, 0.2 ms, 1 Hz) and through
provoking afferent, mechanoreceptive activity by the
stretching of the appropriate muscle. Then, minor adjust-
ments of the electrode position were made to optimize the
characteristic pattern of multi unit MSNA. From the origi-
nal signal, multi-unit MSNA (m-MSNA) bursts were
obtained as the average voltage after ﬁltering (bandwidth of
700–2,000 Hz) and integrating (time constant 0.1 s). The
frequency and amplitude of MSNA bursts were obtained
from bursts with a signal-to-noise ratio of C3[ 15]. Bursts
were identiﬁed using an automated computer program with
preﬁxed settings to exclude observer bias. A preset triangle
with a base of 0.8 s, correlated to the known delay between
R-peak in the electrocardiogram (ECG) and the postgan-
glionic burst, was used to scan the MSNA signal and
identify sympathetic bursts. Hereafter, the maximal and
average amplitude were calculated and potential bursts
were correlated to a percentage of the maximal amplitude.
The computer-derived measures hereafter were visually
conﬁrmed by an investigator so that noise artefacts were not
being counted and if so, noise artefacts were removed. From
the MSNA neurogram the following descriptors were used
in the analysis (1) burst frequency (burst number/min), (2)
burst incidence (burst number/100 heart beats), (3) mean
normalized burst amplitude (burst amplitude normalized to
the maximal burst in the recording) and (4) total normalized
MSNA (sum of normalized burst amplitudes per min) [11].
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line conditions (patient in supine position), which has a high
intra-individual reproducibility [10]. Measurements were
performed between 9:30 and 11:30, to prevent confounding
by circadian variation [9].
Arterial plasma catecholamine levels
After a period of 20 min rest, plasma catecholamine con-
centrations were measured using high-performance liquid
pressure analysis and ﬂuorometric detection [26]. Within
and between-run coefﬁcients of variance (cv’s) for plasma
epinephrine (E) were 4.1 and 8.1% level of 0.166 nmol/l
and for norepinephrine (NE) 4.1 and 6.1% at a level of
1.76 nmol/l, respectively. Analytical detection limits were
0.003 and 0.002 nmol/l for E and NE, respectively.
Catecholamines were collected in ice-chilled 10 ml
Vacutainer tubes (Becton-Dickenson Co., Franklin Lakes,
NJ, USA) containing 0.2 ml of a solution of EGTA
(0.25 mol/L) and gluthatione (0.20 mol/L).
Heart rate and blood pressure
Heart rate was measured continuously for a period of
10 min using a cardiotachometer triggered by the R-wave
of an ECG lead. Simultaneously, intra-arterial systolic and
diastolic blood pressure was measured using a standard
transducer connected to the intra-arterial line. For further
analysis, an average value for the 10-min interval was
calculated for each parameter.
Blood sampling
Arterial blood samples were drawn 40 min after instru-
mentation. Fasting total cholesterol, low-density lipoprotein
(LDL), high-density lipoprotein (HDL) and triglyceride
levels were measured at each visit to assess the effect of
statin therapy.
Statistical analysis
Data are expressed as mean ± SEM unless indicated
otherwise. Prior to the study, sample size needed to ﬁnd a
difference in sympathetic nervous system activity of 20%
with a power of 80% was calculated to be n = 8. Two-way
ANOVA with the factors patient and visit was used to test
the contrast for the difference between the visit during the
withdrawal period and the mean of the visits during statin
treatment. The distribution of some variables was skewed
(heterogeneity) and these were log transformed which
resulted in approximately Gaussian distributions and
removed heterogeneity. A two-tailed p value of\0.05 was
considered to be statistically signiﬁcant.
Results
All eight male patients completed the study: mean NYHA
class (±SD) was 2.6 ± 0.9, age 55 ± 8 years and body
mass index 31.4 ± 6.6 kg/m
2. All patients suffered from
residual myocardial ischemia after a previous myocardial
infarction. Mean LVEF amounted to 30 ± 9% (Table 1).
Seven patients used simvastatin (40 mg daily), one ator-
vastatin (40 mg daily). All patients used a b-blocker (5
patients atenolol, dosage ranging from 50 to 100 mg daily;
2 patients metoprolol (25–200 mg); and one patient biso-
prolol (5 mg daily), all patients were on aspirin and an
ACE-inhibitor (enalapril n = 1, losartan n = 2, perindopril
n = 3, candasartan n = 1, quinapril n = 1). Seven patients
used a diuretic (furosemide n = 2, bumethanide n = 1,
spironolactone n = 4) and one patient used a nitrate. These
baseline medications remained unchanged throughout the
course of the study in all patients.
Sympathetic nerve trafﬁc (microneurography)
After 8 weeks of discontinuation of statins, MSNA was
increased to 73 ± 4 bursts/100 beats (p = 0.01), while
levels during statin were 56 ± 5 and 52 ± 6 bursts/100
beats (Fig. 1). Burst frequency was signiﬁcantly higher
after statin discontinuation (42 ± 3 burst/min without sta-
tin vs. 32 ± 3 and 28 ± 3 burst/min during statin therapy,
p = 0.004). Mean normalized burst amplitude and total
normalized MSNA were signiﬁcantly higher after statin
discontinuation (mean normalized burst amplitude 0.36 ±
0.04 without statin vs. 0.29 ± 0.04 and 0.22 ± 0.04 during
statin, p\0.05; total normalized MSNA 15.70 ± 2.78
without statin, vs. 9.28 ± 1.41 and 6.56 ± 1.8 during sta-
tin, p = 0.009). In one out of the eight patients, we were
unable to obtain qualitatively sufﬁcient microneurography
results to include in the analysis. No difference in MSNA
responses to statins were found between patients with or
without diuretics (or nitrate).
Table 1 Baseline echocardiographic data
Parameter Value (±SD)
EF (%) 30 ± 9
LVIDd (mm) 61 ± 9
RVIDd (mm) 32 ± 6
LVESV (ml) 141 ± 47
LVEDV (ml) 188 ± 55
E/A 1.8 ± 1.3
S/D 1.1 ± 0.6
EF ejection fraction, LVIDd diastolic left ventricle internal diameter,
RVIDd diastolic right ventricle internal diameter, LVESV left ventricle
end-systolic volume, LVEDV left ventricle end-diastolic volume, E/A
mitral valve E/A ratio, S/D pulmonary vein S/D ratio
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and hemodynamics
Discontinuation of statin therapy did not affect arterial
plasma NE and E levels (Table 2). Short-term statin dis-
continuation had no signiﬁcant effect on systolic or dia-
stolic blood pressure and heart rate (Table 1).
Plasma cholesterol levels
Discontinuation of statin therapy resulted in a signiﬁcant
increase in total cholesterol and LDL in all patients
(Table 2), with no signiﬁcant change in HDL cholesterol.
These changes occurred consistently in all patients, con-
sistent with good compliance to the study protocol.
Discussion
The present study provides evidence that statin therapy is
able to suppress MSNA in CHF patients. During statin
withdrawal, MSNA increased signiﬁcantly. Short-term
withdrawal of statins had no effect on arterial plasma cat-
echolamine levels and blood pressure.
Our ﬁndings are in accordance with earlier data obtained
in animal studies [18, 19]. In normolipidemic rabbits with
pacing-induced CHF, incremental doses of simvastatin
reduced the increased renal sympathetic nervous system
activity (RSNA) by nearly 50% compared to untreated
animals. Gao et al. [5] showed a similar decrease in RSNA
by statins in rabbits with pacing-induced CHF. In our
study, MSNA increased by approximately 30% after statin
discontinuation. When compared with the animal studies,
this at a four to eightfold lower mean dosage of statin as
calculated kg
-1 body weight 9 day
-1. A recent study in
patients with coronary artery disease also showed that
atorvastatin shifted sympathovagal balance toward
decreased sympathetic dominance [23]. In contrast, two
prior studies in CHF patients failed to show an effect of
20 mg simvastatin or 10 mg atorvastatin on HRV, but this
might be explained by the relative low-dose of statins used
in these studies [6, 25]. Our patients used twice the dosage
of statins and since previous studies demonstrated a dose–
effect relationship between statins and sympathetic activ-
ity, it is possible that the effects of statins on MSNA are
only apparent at higher statin doses.
To date, the underlying mechanism by which statins
reduce sympathetic outﬂow has not been resolved. Most
hypothesis are derived from animal experimental data.
Statins seem to enhance central nitric oxide (NO) con-
centrations in the paraventricular region, and down regulate
Fig. 1 Muscle sympathetic nerve activity (MSNA) in the individual
CHF patients in bursts/100 heart beats at visit 1 (during statin therapy,
n = 7), visit 2 (8 weeks after statin discontinuation, n = 7) and visit
3 (4 weeks after statin restart, n = 6). MSNA was signiﬁcantly higher
after statin discontinuation. * P = 0.01
Table 2 Statin effects
BP blood pressure, E arterial
plasma epinephrine
concentration, HDL high
density lipoprotein, LDL low
density lipoprotein, MAP mean
arterial pressure, MSNA muscle
nerve sympathetic activity, NE
arterial plasma norepinephrine
concentration
* P\0.05 versus statin
Visit 1 (statin) Visit 2 (no statin) Visit 3 (statin)
MSNA (bursts/100 beats) 56 ± 57 3 ± 4* 52 ± 6
MSNA (burst/min) 32 ± 34 2 ± 3* 28 ± 3
MSNA (mean normalized amplitude) 0.29 ± 0.04 0.36 ± 0.04* 0.22 ± 0.04
MSNA (normalized total MSNA) 9.28 ± 1.41 15.70 ± 2.78* 6.56 ± 1.83
NE (pg/ml) 323 ± 47 286 ± 39 275 ± 47
E (pg/ml) 40 ± 72 9 ± 43 1 ± 4
Systolic BP (mmHg) 116 ± 5 118 ± 6 117 ± 9
Diastolic BP (mmHg) 61 ± 36 5 ± 36 0 ± 3
MAP (mmHg) 83 ± 38 5 ± 48 2 ± 5
Heart rate (bpm) 59 ± 26 0 ± 35 7 ± 3
Total plasma cholesterol (mmol/L) 3.4 ± 0.4 5.5 ± 0.5* 3.5 ± 0.4
LDL (mmol/L) 1.8 ± 0.4 3.5 ± 0.4* 1.7 ± 0.2
HDL (mmol/L) 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1
Triglycerides (mmol/L) 1.4 ± 0.2 2.5 ± 0.4 2.4 ± 1.2
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formation in the rostral ventrolateral medulla (RVLM)
[5, 12]. Increases in central Ang II concentrations as seen
in CHF, stimulate and upregulate the AT1-receptor as
well as NAD(P)H-oxidase expression [5]. Stimulating the
AT1-receptor in turn stimulates NAD(P)H-oxidase, result-
ing in increased reactive oxygen species (ROS) formation
[5]. ROS increases sympathetic outﬂow in a number of ways.
First, increases in ROS concentrations seem to reduce
cerebral NO, a sympathoinhibitory substance [14]. Formed
NO is immediately converted to peroxynitrite at high levels
of intracerebral superoxide generation. Because NO is a
well-known sympathoinhibitory substance, a reduction in
bioavailability of NO, would predispose local neurons in
the hypothalamus and medulla to become more excitable
and thereby generate an enhanced sympathetic outﬂow.
Superoxide anion has also been shown to modulate cal-
cium-channel function in the central nervous system [28].
This mechanism may contribute to neuronal excitability.
Additionally, NO itself has also demonstrated to have a
regulatory role on sympathetic outﬂow at a central level
[17]. Although it is not exactly known how NO modulates
sympathetic outﬂow, several scenarios have been sug-
gested. Of these, the most important is the suggestion that
NO production by neuronal nitric oxide synthase (nNOS)
causes c-amino butyric acid (GABA) release, that in turn
produces a reduction in sympathetic outﬂow [27]. Abnor-
malities in the NO-mechanism may contribute to the high
sympathetic output state of CHF and hypertension. Gao
et al. [5] demonstrated in CHF rabbits that treatment with
simvastatin down regulated AT1-receptor mRNA and
protein expression and NAD(P)H oxidase components in
the RVLM. If statins downregulate Angiotensin Type-1
receptor expression and NAD(P)H formation, as well as
increase NO formation, this might offer a potential expla-
nation how statins can reduce central sympathetic outﬂow.
The current study, however, cannot differentiate between
these mechanisms.
In our study, the changes in MSNA were not translated
in a decrease in arterial plasma NE levels. How can this be
explained? It might be possible that for an effect on plasma
NE levels, higher doses of statins might be required. This is
supported by a study in pacing-induced CHF rabbits [20].
Plasma NE concentrations were only reduced when
administering statin doses up to 3 mg/kg/day, e.g. [18].
This dose level exceeds by far the normal human statin
dose that was used in our study. In the low-dose group
(0.3 mg/kg/day), plasma NE concentrations were not
affected and this is in agreement with our study where the
mean statin dosage was 0.4 mg/kg/day. Higher doses may
be able to suppress plasma NE levels as is suggested by
a recent study, demonstrating a signiﬁcant reduction in
plasma NE concentrations after administering atorvastatin
in a dose of 80 mg to patients with coronary artery disease
[23]. Thus, the lack of change in plasma arterial NE levels
is in accordance with animal studies and may be explained
by the relative low statin dose. An alternative explanation
might be that the plasma NE level is the net result of
plasma NE spillover and NE clearance. A decrease in
neuronal NE release by the decrease in MSNA might be
translated into a decreased plasma NE spillover. However,
a concomitant increase in plasma NE clearance might mask
any effect of plasma NE spillover on plasma NE levels,
leaving the latter unaltered. Finally, it should be noted that
MSNA reﬂects only the sympathetic outﬂow to the muscle
compartment while plasma NE levels represent merely
global total body sympathetic nerve activity. So, even if
statins reduce sympathetic nerve trafﬁc to the muscle
compartment, any contrasting change in sympathetic nerve
trafﬁc to another compartment might result in an unaltered
plasma NE level.
In line with the decrease in sympathetic nerve trafﬁc,
one would expect a decrease in blood pressure or heart rate
but this was not observed. This is probably due to the fact
that effects on blood pressure and heart rate are also
determined by other compensatory regulatory mechanisms
like the renin-angiotensin-aldosterone system [22].
Although non-compliance to the drug might also explain
this effect, the decrease in plasma lipids in all patients
argues against this possibility. Alternatively, the sympath-
oinhibitory effect of this dose statins is not large enough to
be translated into a decrease in blood pressure or heart rate.
Despite a reduction in plasma NE levels, statin doses as
high as 3 mg/kg/day did not affect hemodynamics in CHF
rabbits [18].
One may question whether the sympathoinhibitory
effect of statin therapy would have any additional beneﬁ-
cial effect on top of betablocking therapy in patients with
CHF. Beta-adrenoreceptor antagonists protect the cardio-
vascular system from sympathetic stimulation by block-
ing the b-adrenoceptors. However, vascular postsynaptic
a-adrenoreceptors are left unblocked and are therefore still
operational in determining peripheral vascular resistance.
The uninterrupted stimulating effect of increased sympa-
thetic nerve trafﬁc on these a-adrenoreceptors might be
detrimental for the cardiovascular system [20]. If statins
indeed reduce sympathetic outﬂow, as suggested by our
study, they may offer an additional pathway to counteract
the increased sympathetic tone, thereby reducing its detri-
mental effects [20]. Two recent large clinical trials (GISSI-
HF and CORONA) could not establish a beneﬁcial effect
of statins on clinical outcome in CHF patients [7, 13]. This
suggests that the reduction of sympathetic nerve trafﬁc by
statins is possibly insufﬁcient to be translated into beneﬁ-
cial effects on long-term cardiovascular morbidity and
mortality. An alternative explanation is that CHF in these
Clin Auton Res (2010) 20:73–78 77
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disorders or that different statins and/or doses that were
used in these studies.
In conclusion, the results of this study suggest that
statins may have a sympathoinhibitory in patients with
CHF. If this effect is conﬁrmed by larger scale studies,
statins might play an additional protective role in cardio-
vascular patients apart from their effects on lipids, since an
increased sympathetic tone may be detrimental on the long
term.
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